The Medical Advisor

Introduction: The Problem with Conventional Trials The FDA and mainstream oncology focus almost exclusively on genetic-targeted therapies and single-drug clinical trials. While this approach has yielded breakthroughs in some cancers, it misses a critical opportunity : the synergistic effects of drug combinations targeting tumor metabolism . Standard RCTs are expensive, slow, and designed to satisfy regulatory requirements, not explore every scientifically plausible drug synergy. Millions of combinations of repurposed drugs, dietary interventions, and metabolic modulators will never be formally tested . Enter AI-driven simulations: a cost-effective, high-throughput method to predict which combinations may be most effective — before a single patient trial begins. 1. How AI Simulations Work in Cancer Therapy Modern AI models integrate: Tumor metabolic pathways — Warburg effect, mitochondrial dysfunction, nutrient dependencies Drug mechanisms — Metformin, fenbendazole, ivermectin, methy...

Dr. Thomas N. Seyfried, PhD, Professor of Biology at Boston College, has been singing the praises of an ancestral diet for treating the modern disease of cancer for years… and with good reason. His theory that cancer is a metabolic disease sounds almost too simplistic, and yet makes perfect sense when you understand what drives cancer’s growth. Standard of Care: The Cut, Poison and Burn Method and Its Miserable Success Record Seyfried is not a fan of conventional medical cancer treatments. As he states in his groundbreaking book, Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer, the majority of today’s health care practitioners are required to prescribe conventional cancer treatments like chemotherapy and radiation—despite their toxicity and the possibility that they encourage new tumor growth. In fact, if a physician does not include these modalities in a treatment plan, the physician may be at risk of losing his medical ...